INTRODUCTION AND AIMS: Ketoanalogues (KA) were shown, by some of the studies, to reduce proteinuria, improve renal function and nutritional status in patient population with diabetic nephropathy. This beneficial effect may be through the suppression of inflammation. We aimed to compare the status of inflammatory markers in rats treated with both KA and protein restricted diet to rats with restricted diet only. METHODS: Study was performed on 22 Sprague Dawley rats in Research Center. Rats were given streptozocine intraperitoneally at the dose of 65 mg/kg. 20 rats with blood sugar level equal to or above 300 mg/dl at 48 th hours were accepted as diabetic. These rats were fed with normal diet until 5 th week of the study where diabetic nephropathy was determined by 24 hours urine analysis. 18 of 20 rats were diagnosed with diabetic nephropathy and were randomly divided into two interventional groups each group containing 9 rats. Group I (control group) received low protein diet (10% protein), group II (study group) received keto amino acids (35-70mg/kg) with gavage along with low protein diet. The treatment continued for 2 weeks. Rats were weighted both at the onset and end of the study. Blood samples were obtained at 5th and 7th weeks of treatment for measurement of albumin, creatinine, interleukin (IL)-1, IL-6, IL-10, IL-18 and tumor necrosis factor (TNF)-alfa. (Table 1) . RESULTS: Rats had similar weights and blood sugar at the beginning of the study. After two weeks period, following separation of the groups, there were no significant difference observed at weight, blood sugar and serum creatinine levels (p¼ 0,309, 0,302, 0,552 respectively). It was seen that study group has higher results for albumin levels than control group (p&gt0,001). All the inflammatory markers except IL -1 were either decreased or not changed in study group making a significant difference to control group, which can lead to the understanding of decreased inflammation in KA used group. CONCLUSIONS: Low protein diet is the only method proven to slow the progression of diabetic nephropathy. But malnutrition due to insufficient protein intake is a frequent side effect of consuming low protein diets. Our study showed KA may be used as a diet supplement to prevent both malnutrition and decrease the inflammatory response to protect progression towards end stage renal disease.
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INTRODUCTION AND AIMS:
In Albania, as in other development countries diabetic nephropathy is becoming an important cause of end-stage renal disease. Recent data reported the important role of dyslipidaemia in the progression of kidney disease in patients with diabetes. Actually, little information exists on the prevalence and the control of dyslipidaemia among our patients with diabetic nephropathy. The aim of this study was to determine the prevalence of dyslipidaemia in a cohort of diabetic patients with overt nephropathy in a Tirana hospital for further development of preventable strategies in this population. METHODS: Diabetic patients attending Diabetology and Nephrology Clinic during one year were included in the study. A total of 192 diabetic patients with overt diabetic nephropathy were assigned to 78 age-and sex-matched normo albuminuric diabetic patients. Fasting lipid profile, blood sugar, and renal function tests were evaluated. RESULTS: Total serum cholesterol and serum triglycerides were significantly higher in patients with overt diabetic nephropathy compared to the controls; 78.7% and 60.5% versus 20.8% and 32.6%, respectively (p ¼ 0.001 and 0.002, respectively). Low-density lipoprotein-cholesterol (LDL) level was significantly higher in diabetic patients with albuminuria compared with those normoalbuminuric (p<0.001). LDL at the target level was found more frequent in the group of normoalbuminuric diabetic men compared to those with overt nephropathy (35.7% versus 18.9%). Patients with diabetic nephropathy showed higher level of triglyceride (TG) and there was no difference according to the sex. In addition, few patients received adequately the treatment prescribed for dyslipidaemia and even among patients who were on lipid-lowering treatment, the majority of individuals remained uncontrolled. CONCLUSIONS: Lipid profile of patients with overt diabetic nephropathy was comparable with that reported before. Most importantly we found that dyslipidaemia was not adequately controlled and potential precautions should be taken regarding the followup of patients with diabetic nephropathy. 
